Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma
Cohort 2 showed 60% objective response rate, 30% complete response rate 90% overall survival rate…
Cohort 2 showed 60% objective response rate, 30% complete response rate 90% overall survival rate…
Cohort 2 showed 60% objective response rate, 30% complete response rate 90% overall survival rate…
Please read the full announcement in the attached PDF Attachment 2021_40_CompanyAnnouncement
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage…
Company to Host Conference Call and Live Q&A Session, August 26, 2021, at 10:00am PT/ 1:00pm…
BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or…
Common stock and warrants to commence trading on Nasdaq on August 12, 2021 under the…
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:…
–Company to Host Conference Call August 17, 2021 at 8:30AM ET– RADNOR, Pa., Aug. 11,…
Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small…
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology…
WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or…
MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16,…
TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales ANN ARBOR, Mich., Aug. 11,…
FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation…
-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the…
– Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib –– Additional Phase 1/2…
Completed investigational new drug (“IND”) enabling studies for lead program, BMF-219, an irreversibly binding menin…